A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...